Patienter, der er i behandling med Retacrit, har ofte behov for en forhøjet dosis af en særlig, blodfortyndende medicin (heparin) under hæmodialyse for at minimere risikoen for blodpropper.
An increase in the dose of a particular blood-thinning medicine (heparin) during haemodialysis is often needed during the course of therapy with Retacrit to minimize the risk of blood clotting.